Arvinas, Inc. (ARVN): Shareholders' Equity
$433.90M
As of 2025-12-31
$562.20M
As of 2026-06-30
-8.4%
3-year compound annual growth
-7.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $433.90M | -22.8% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $561.70M | -14.9% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $660.00M | +16.8% | 2026-02-24, Balance as of period end |
| 2022-12-31 | $564.90M | -27.7% | 2025-02-11, Balance as of period end |
| 2021-12-31 | $781.70M | +21.7% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $642.20M | +183.4% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $226.60M | +65.8% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $136.67M | n/m | 2021-03-01, Balance as of period end |
| 2017-12-31 | -$61.23M | n/a | 2019-03-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | $433.90M | -22.8% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $1.02B | +22.5% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $307.42M | +453.3% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $364.05M | -13.6% |
| Harrow, Inc. (HROW) | 2025-12-31 | $52.45M | -24.7% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $631.00M | +30.1% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $303.13M | -47.0% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $13.69M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $32.61M | n/m |
Compare ARVN, LGND, VREOF, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗